GoodRx Hopes to Play a Role in TrumpRx, CEO Says. The Stock Rises.
Oct 09, 2025 14:10:00 -0400 by Nate Wolf | #Healthcare
President Donald Trump announced plans to launch a government-run website to buy drugs directly from pharmaceutical companies. (Getty Images)
Key Points
- GoodRx is in discussions with the Trump administration about joining TrumpRx, Reuters reported.
- TrumpRx, slated to launch in 2026, will direct consumers to drug manufacturers’ sites for purchases, not fulfill orders itself.
- GoodRx stock rose on Thursday.
The medication savings platform GoodRx hopes to partner with the Trump administration on TrumpRx, the government’s planned drug-buying website.
“We are excited about the prospect of working with the administration to bring TrumpRx to life and have been engaged in conversations about what this could look like,” GoodRx CEO Wendy Barnes said in an emailed statement to Barron’s. “We hope we can find a way to partner on this endeavor.”
The company didn’t say whether these discussions were with the administration or other partners.
“As long as drugmakers deliver cost savings for American patients through TrumpRx, how they do so is irrelevant,” White House spokesman Kush Desai told Barron’s in a statement.
President Donald Trump last month announced plans to launch a government-run website called TrumpRx for consumers to buy drugs directly from pharmaceutical companies.
A Trump administration official said TrumpRx will list drugs and redirect Americans to manufacturers’ sites to purchase them, but it won’t fulfill those orders. TrumpRx is slated to launch in 2026.
GoodRx isn’t a drug manufacturer, but CEO Barnes said the company could work with TrumpRx in two ways. GoodRx could either power TrumpRx directly and make the drugs available at more than 70,000 retail pharmacies, or it could add TrumpRx cash prices to the GoodRx platform.
“We believe GoodRx is the most capable partner to make this vision a reality and to ensure Americans can save time and money on their prescriptions,” Barnes said.
GoodRx stock rose 5.7% on Thursday, when news of its potential involvement in TrumpRx first broke. It was up another 1.1% in premarket trading Friday.
Shares have slipped 0.2% in 2025 and fallen about 33% over the past 12 months as of Thursday’s close.
Write to Nate Wolf at nate.wolf@barrons.com